Get the Stockscreener App
2.08
2.35%
-0.05
After Hours:
2.08
Opus Genetics Inc stock is traded at $2.08, with a volume of 217.35K.
It is down -2.35% in the last 24 hours and down -8.37% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$2.13
Open:
$2.12
24h Volume:
217.35K
Relative Volume:
0.43
Market Cap:
$143.45M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-1.9083
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
+6.67%
1M Performance:
-8.37%
6M Performance:
+108.00%
1Y Performance:
+44.44%
1-Day Range:
$2.05
$2.1563
1-Week Range:
$1.9358
$2.33
52-Week Range:
$0.65
$2.5907
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
2.08 | 146.89M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - Defense World
Independent Chairman of Opus Genetics Picks Up 9.5% More Stock - simplywall.st
Caprolactam Chemicals Limited Stock Analysis Technical Signals for YEAR - earlytimes.in
What drives Opus Genetics Inc stock priceEx-Dividend Date Alerts & Small Investment Portfolio - earlytimes.in
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Bridgewater Associates, AQR Capital Management, Schonfeld Strategic Advisors, D.E. Shaw, Millennium Management, Elliott Management, Discovery Capital Management, Opus Genetics Inc - Insider Monkey
Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update - MSN
Portfolio Shifts: How Opus Genetics Inc stock performs in stagflationWeekly Market Outlook & Low Risk High Reward Trade Ideas - moha.gov.vn
Opus Genetics (NASDAQ:IRD) Director Cam Gallagher Purchases 83,000 Shares - MarketBeat
Shorts Report: Why Opus Genetics Inc R3X1 stock is upgraded to buy - moha.gov.vn
B Riley Securities initiates coverage of Opus Genetics (IRD) with buy recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Soaring Eagle Acquisition Corp Equity Warrant Stock Analysis and ForecastLong-Term Growth Stocks & Superior Capital Appreciation - earlytimes.in
Opus Genetics Inc R3X1 Stock Analysis and ForecastMarket Insider Reports & Discover Strategies with Fellow Traders - earlytimes.in
MACD Signals Flash Warning for Compucom Software Limited StockMACD Trading Signals & Minimal Investment Big Returns - earlytimes.in
Opus Genetics rises as eye disease study to proceed without changes - MSN
Rate Hike: Why Opus Genetics Inc stock could benefit from AI revolutionInsider Selling & Proven Capital Preservation Tips - moha.gov.vn
Will Opus Genetics Inc. stock outperform growth indexesProfit Target & Consistent Growth Equity Picks - Улправда
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Will Opus Genetics Inc. stock gain from lower inflationMarket Growth Summary & Low Risk Profit Maximizing Plans - Улправда
Opus Genetics partner files supplemental NDA for presbyopia drug - MSN
Why Opus Genetics Inc. stock is a value investor pick2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Bank Watch: Is Opus Genetics Inc. stock attractive for growth ETFsMarket Volume Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics Earnings Notes - Trefis
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock - MarketBeat
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) By Investing.com - Investing.com South Africa
Opus Genetics (IRD) Price Target Increased by 13.45% to 7.87 - MSN
Foundation Fighting Blindness Retinal Degeneration Fund Sells 4,000,000 Shares of Opus Genetics Inc (IRD) - GuruFocus
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) - Investing.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | Associated Press | syndication news - Enidnews.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - marketscreener.com
Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27% - simplywall.st
B. Riley Securities Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
B. Riley Initiates Opus Genetics at Buy With $9 Price Target - marketscreener.com
B.Riley initiates Opus Genetics stock with Buy rating on gene therapy potential - Investing.com Canada
Opus Genetics Says Independent Panel Backs Phase 1/2 Trial in Best Disease After Safety Review - marketscreener.com
Opus Genetics rises on update from eye disease study (IRD) - Seeking Alpha
Opus Genetics (IRD) Advances in Clinical Trial for Best Disease Treatment - GuruFocus
Opus Genetics advances Best disease gene therapy trial after positive safety review - Investing.com Canada
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease - The Manila Times
Opus Genetics Announces Positive Recommendation from - GlobeNewswire
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Is Opus Genetics Inc. stock positioned well for digital economy2025 Earnings Impact & Daily Market Momentum Tracking - Newser
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades after rate cutsMarket Risk Analysis & Smart Allocation Stock Reports - Newser
Why Opus Genetics Inc. (R3X1) stock gets analyst attentionOptions Play & High Accuracy Trade Signal Alerts - Newser
Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings - MarketBeat
How Opus Genetics Inc. (R3X1) stock trades under stagflationAnalyst Downgrade & Fast Entry High Yield Stock Tips - Newser
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opus Genetics Inc Stock (IRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gallagher Cam | Director |
Dec 29 '25 |
Buy |
1.98 |
81,000 |
160,275 |
1,891,430 |
| Foundation Fighting Blindness | Director |
Dec 09 '25 |
Sale |
2.15 |
4,000,000 |
8,600,000 |
5,492,171 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):